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Stenting vs above knee polytetrafluoroethylene
bypass for TransAtlantic Inter-Society Consensus-II
C and D superficial femoral artery disease
Hasan H. Dosluoglu, MD,a,b Gregory S. Cherr, MD,b Purandath Lall, MBBS,a,b Linda M. Harris, MD,b
and Maciej L. Dryjski, MD,b Buffalo, NY
Objectives: TransAtlantic Society Consensus (TASC)-II recommends bypass for TASC D and low-risk patients with
TASC C lesions but does not specify graft types. Percutaneous balloon angioplasty/stenting (PTA/S) and above knee
femoropopliteal bypass (AK-FPB) using polytetrafluoroethylene (PTFE) for these lesions were compared to determine if
graft type should be part of the TASC-II recommendations for the treatment of TASC C lesions.
Methods: Consecutive patients who underwent AK-FPB with PTFE, or PTA/S for TASC-II C (PTA/S-C) or D
(PTA/S-D) SFA lesions between June 2001 and April 2007 were retrospectively analyzed. The primary end points were
primary, assisted-primary, and secondary patency rates.
Results: In 127 patients (mean age, 68.7  10.0 years; median, 68; range, 49-97), 139 limbs were treated (46 AK-FPB,
49 PTA/S-C, 44 PTA/S-D). The mean occlusion and stented lengths were 9.9 3.8 and 24.3 6.6 cm (median, 10 and
20 cm) in PTA/S-C, and 26.6 5.5 and 30.0 5.2 cm (median, 26 and 29 cm) in PTA/S-D. Technical success was 84%
in PTA/S-D and 100% in other groups. Mean follow-up was 26.4  18.0 months (median, 24). The 12- and 24-month
primary patency was 83% 6% and 80% 7% for PTA/S-C; 54% 8% and 28% 12% for PTA/S-D; and 81% 6% and
75% 7% for AK-FPB (P< .001 PTA/S-D vs PTA/S-C and AK-FPB); assisted-primary patency was 95% 3% and 95%
 3% for PTA/S-C, 62%  8% and 49%  10% for PTA/S-D, and 81%  6% and 75%  7% for AK-FPB (P < .001,
PTA/S-C vs PTA/S-D; P  .003, PTA/S-C vs AK-FPB; and P  .03, PTA/S-D vs AK-FPB). Secondary patency was
98%  3% and 98%  3% for PTA/S-C; 72 %  7% and 54%  11% for PTA/S-D, and 81%  6% and 78%  7% for
AK-FPB. Secondary patency was significantly better in PTA/S-C than AK-FPB (P  .003) and PTA/S-D groups (P <
.001). The difference was marginally better in AK-FPB than in PTA/S-D (P  .064).
Conclusions: PTA/S for TASC-II C lesions has a superior midterm patency than AK-FPB using PTFE, and AK-FPB with
PTFE has better primary and assisted-primary patency than PTA/S-D. The TASC-II recommendations should be
modified to recommend treatment of SFA TASC-II C lesions by PTA/S rather than PTFE bypass for all patients. PTA/S
of TASC-II D lesions should only be considered in high-risk patients who cannot tolerate a bypass procedure using PTFE.
(J Vasc Surg 2008;48:1166-74.)The rapid development of endovascular interventions
and their adoption by vascular surgeons have revolution-
ized the treatment of patients with peripheral arterial dis-
ease. The superficial femoral artery (SFA) is one of the most
commonly intervened-on arteries; however, the optimal
approach for treating this artery is still debated.1-19
The optimal approach for each patient is determined by
lesion complexity, indication for intervention, and the
overall condition of the patient. The original TransAtlantic
Inter-Society Consensus (TASC) classification20 defined
TASCC as a single stenosis or occlusion5 cm, ormultiple
stenoses or occlusions each between 3 and 5 cm; however,
TASC-II, the newer version, defines TASC-II C lesions as
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1166multiple stenoses or occlusions totaling 15 cm.21 Al-
though the recommended treatment for TASC-II C lesions
is surgical bypass, patient comorbidities, fully informed
patient preference, and the operator’s long-term success are
suggested to be important factors in making treatment
recommendations for each patient.21 The recommenda-
tions, however, do not specify the graft type (synthetic vs
autologous vein) to be used for bypass procedures in these
patients.
Increasingly, endovascular therapy is successfully used
for complex SFA lesions with long occlusions. Although
primary balloon angioplasty with selective stenting is used
in less severe lesions,1 primary stenting is still the most com-
mon treatment for long occlusions in the SFA, and 12-month
primary patency rates have been 50% to 90% in recent years.1,3-9
Subintimal angioplasty with selective stenting10-15 and revascu-
larization using covered stents16-18,22 have also been increas-
ingly used, with promising results.
Several randomized studies have documented superior
patency rates for above knee (AK) femoropopliteal bypass
(FPB) using great saphenous vein (GSV) compared with
prosthetic grafts,23-25 Polytetrafluoroethylene (PTFE)
grafts are still widely used for the AK position. Justification
for using PTFE grafts for AK femoropopliteal bypass in-
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from early studies.26,27 However, a review of 25 studies
showed that AK-FPB using GSV has better patency rates at
each time point,28 and a more recent meta-analysis of 75
studies found that the difference was more pronounced in
patients with critical limb ischemia (CLI).29
Considering the significant difference between FPB
using prosthetic or GSV grafts as conduits, our aim was to
compare our results of PTA/S for TASC-II C and D SFA
lesions with results in patients who underwent FPB using
PTFE, and to determine if graft type should be incorpo-
rated into the TASC-II recommendations for the treatment
of TASC C lesions.
MATERIAL AND METHODS
Design. All consecutive patients who presented to the
Veterans Administration Western New York Healthcare
System between June 1, 2001, and April 1, 2007, who
underwent an AK-FPB with PTFE (AK-FPB group), or
PTA/S for TASC-II C (PTA/S-C group) or D (PTA/S-D
group) SFA lesions for disabling claudication or CLI
(Rutherford 3-6)30 were identified, and retrospectively an-
alyzed from our prospectively maintained database. Insti-
tutional Review Board approval was obtained. Patients with
isolated common femoral artery occlusion, popliteal artery
lesions extending to the P2 segment (popliteal artery seg-
ment in the popliteal fossa extending to the knee joint),
isolated popliteal occlusions, and those who had previous
bypass procedures were not included. Also excluded were
patients whose lesions were initially staged as TASC C, but
were down-staged to TASC-II B after the TASC II recom-
mendations were published.
Methodology. Demographics, comorbidities, clinical
presentation, noninvasive arterial studies, angiograms,
TASC-II classification14 of the treated lesions, length of
occlusions and stenoses, number of runoff vessels, number
of stents, total stented vessel length, postoperative course,
hospital length of stay (LOS), follow-up arterial studies,
patency, and status of limbs on last follow-up were prospec-
tively entered into our database. The preoperative angio-
grams were analyzed, and TASC-II category of the SFA
lesions in patients who underwent AK-FPBwas determined
in 44 patients. The angiograms were not available in the
remaining two patients, and the TASC-II category could be
determined by the dictated report.
All endovascular procedures were performed by vascu-
lar surgeons in the operating room using the OEC 9800
system (General Electric Medical Systems, Salt Lake City,
Utah). All interventions were performed by a contralateral
femoral artery approach using 6F sheaths. Most lesions
were crossed using a combination of Glidewire (Terumo,
Somerset, NJ) and 4F or 5F Glidecath (Terumo). Intralu-
minal crossing was intended for all cases. The actual cross-
ing method was recorded as intraluminal, subintimal, or a
combination of the two. An intravascular ultrasound-
guided reentry device (Pioneer catheter, Medtronic, Santa
Rosa, Calif) was used in five patients (4 successfully). Predi-
lation with a 4-mm 10-cm balloon was used, followed bystent placement in all cases (Smart, Cordis, Johnson and
Johnson, Miami Lakes, Fla). The size of the stent and
postdilation balloon diameter were estimated by compar-
ing the target size with the 4-mm predilation balloon.Most
commonly used stent diameters were 6 and 7 mm. Postdi-
latation angioplasty was always performed with a 5- or
6-mm balloon. When multiple stents were used, the over-
lap was 0.5 to 1 cm. True flush SFA occlusions were not
attempted by endovascular means.
Clopidogrel bisulfate (75 mg) was started before the
planned procedure, or was started in the recovery room
(300 mg). All patients continued to take clopidogrel (75
mg) and enteric-coated acetylsalicylic acid (ASA; 81 mg)
for a minimum of 30 days, followed by lifelong ASA ther-
apy.
AK bypasses were preferentially performed using 7-mm
PTFE grafts, and the selection was based on the diameter of
the popliteal artery (72% had 7mm, 24% had 6mm, and 4%
had 8 mm grafts). Postoperatively, all patients who had
AK-FPB continued to receive ASA, or clopidogrel when
ASA could not be used, unless the patient was taking
warfarin.
An increasingly aggressive endovascular-first approach
was adopted for all patients starting from 2002. The deci-
sion to proceed with endovascular intervention or open
bypass was made by the vascular surgeon, with increasing
attempts for endovascular revascularization during the
study period. Most (83%) of the AK-FPB with PTFE were
performed before January 2004 and comprise 83% of all the
interventions performed during this period. After that time,
only eight (17%) additional AK-FPB with PTFE were per-
formed, and this represented only 9% of the cases per-
formed during that period in this cohort. During the same
time period, only two patients underwent FPB to an AK
segment using vein grafts and were excluded.
All patients were followed up by clinical assessment and
by our vascular laboratory during the first postoperative
visit (1 to 4 weeks), and at 3, 6 months, and every 6 months
thereafter for ankle-brachial index (ABI) measurements,
graft or stent velocities and patency, by duplex ultrasound
(DUS) imaging. All patients with wounds were monitored
in our vascular surgery wound clinic until wounds were all
healed. Angiography was performed when noninvasive
studies suggested restenosis or occlusion or when adequacy
of the patency or adequacy of foot perfusion was in ques-
tion due to suboptimal DUS imaging or lack of clinical
improvement. Restenosis was defined as 50% decrease in
luminal diameter seen on angiography or DUS imaging, as
defined by an elevated ratio of greater than four times the
velocity of the more proximal segment. Reinterventions
were performed to assist patency, or when clinically indi-
cated (recurrent claudication, nonhealing wound, recur-
rent ulcer or pain), and Society for Vascular Surgery (SVS)
reporting standards for lower extremity arterial procedures
were followed.29
Definitions. TASC-II C lesions included those with
multiple stenoses or occlusions totaling 15 cm with or
without heavy calcification, and TASC-II D lesions in-
onsen
JOURNAL OF VASCULAR SURGERY
November 20081168 Dosluoglu et alcluded chronic total occlusions of SFA (20 cm). A patent
runoff vessel was defined as an infrapopliteal vessel without
a hemodynamically significant (50%) angiographic steno-
sis distal to the treated site,30 and the number of adequately
patent runoff vessels (0 to 3) was calculated after all inter-
ventions were completed for that limb. Technical success
was defined as a patent vessel with 30% residual angio-
graphic stenosis after the intervention. Diabetes mellitus
(DM) was defined as fasting plasma glucose110mg/dL or
a hemoglobin A1c 7%. Noninsulin dependent DM
(NIDDM)was defined as a patientwhodid not receive insulin
therapy for management of DM, and insulin-dependent DM
(IDDM) was defined as a patient who routinely received
insulin therapy.
Statistical analysis. Data analysis was performed us-
ing SPSS 15.0 software (SPSS Inc, Chicago, IL). Kaplan-
Meier analysis and log-rank test were used to compare
groups for primary patency, assisted-primary patency, sec-
ondary patency, limb salvage, and overall survival on an
intent-to-treat basis. Recanalization failures were recorded
as treatment failures at time 0. Demographic comparisons
were made using two-tailed 2 or Fisher exact test for
categoric variables, and by the Student t test or Mann-
Whitney U test for continuous variables with or without
normal distribution, respectively. Univariate analyses were
performed for identifying factors predicting limb loss, and
multivariate analysis was performed using Cox proportional
regression to identify the independent predictors of pri-
mary patency. Values of P  .05 were considered signifi-
cant.
RESULTS
A total of 127 consecutive patients (139 limbs, 125
male) were treated (46 in AK-FPB, 49 in PTA/S-C and 44
in PTA/S-D). The median age was 68.7  10.0 years
(range, 49-97 years), Demographics, comorbidities, and
indications are reported in Table I. The patients in PTA/
S-C and PTA/S-D were older than AK-FPB patients (P 
Table I. Demographic characteristics, comorbidities, and
Variable AK-FPB
Age, mean  SD years 64.7  8.0
CAD, % 63
Hypertension, % 74
Diabetes mellitus, % 52
CVA, % 11
Dyslipidemia, % 63
COPD, % 30
Renal, % 7
Dialysis, % 2
Smoker (active), % 67
DC, % 57
Tissue loss, % 30
AK-FPB, Above-knee femoropopliteal bypass group; CAD, coronary arter
disease; DC, disabling claudication; PTA/S-C, percutaneous balloon angio
percutaneous balloon angioplasty/stenting in TransAtlantic Inter-Society C
Note: aP  .001 and bP  .068 vs AK-FPB..001, AK-FPB vs PTA/S-C; P  .068, AK-FPB vs PTA/S-D). The AK-FPB group had fewer patients than the other
groups with renal insufficiency and CLI, but more active
smokers. More patients in PTA/S-D group had hypercho-
lesterolemia. In patients who had AK-FPB, eight (17%) had
TASC B, seven had TASC C (15%), and the remaining 31
(67%) had TASC D lesions.
The mean occlusion and stented lengths were 9.9 
3.8 cm (median, 10; range, 2-16 cm), 24.3  6.6 cm in
PTA/S-C (median, 20; range, 10-40 cm; 2.9 0.9 stents),
and 26.6 5.5 cm (median, 26; range, 15-38 cm), 30.0
5.2 cm in PTA/S-D (median, 29; range, 19-40 cm, 3.5 
0.8 stents). Primary technical success was 100% in PTA/
S-C group, whereas in PTA/S-D recanalization failed in
seven patients (success rate, 84%). Of the failures, two had
immediate FPB, one patient had below knee (BK) FPB
using saphenous vein graft 4 weeks later, and one had a
successful stenting of his SFA 3 months later. One patient
with venous ulcers had PTA/S of his severe external iliac
artery stenosis had complete wound healing. One patient
underwent an AK amputation (AKA) within 2 months, and
one patient died 2 months later without further interven-
tion. The causes of failure were extreme calcification in two
and inability to reenter the distal true lumen in five patients.
Successful crossing of SFA occlusions were recorded as
intraluminal in 73%, subintimal in 8%, and mixed in 19% of
patients in PTA/S-C, and 24%, 16% and 70% respectively in
PTA/S-D (P  .001).
The number of patent runoff vessels was 2.1  0.7
(median, 2; range, 1-3) in AK-FPB, 1.7  08 (median, 2;
range, 0-3) in PTA/S-C (P  .045 vs AK-FPB) and 1.8 
0.7 (median, 2; range, 0-3) in PTA/S-D (P  .069 vs
AK-FPB). There were more patients in whom in-line flow
to the foot was not achieved in PTA/S-D (16%) than in the
other groups (PTA/S-C, 2%; AK-FPB, 0%; P .001). Five
of these eight patients eventually had a major amputation.
The ABI was reliable only in 72% of patients, and increased
from 0.46 0.19 to 0.90 0.09 in AK-FPB, 0.54 0.21
to 0.93  0.10 in PTA/S-C, and 0.53  0.12 to 0.95 
ations for intervention between groups
A/S-C PTA/S-D P
 10.4a 69.4  10.2b See note
65 70 .460
78 80 .526
67 55 .804
18 20 .221
69 84 .027
22 27 .727
31 20 .091
6 7 .283
37 39 .006
20 27 .001
73 61 .001
ase; CVA, cerebrovascular accident; COPD, chronic obstructive occlusive
stenting in TransAtlantic Inter-Society Consensus-II C group; PTA/S-D,
sus-II D group.indic
PT
71.6
y dise
plasty/0.11 in PTA/S-D.
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2-19 days) for AK-FPB, 3.3  4.7 days (median, 2; range,
0-26 days) for PTA/S-C, and 2.8  3.8 days (median, 1;
range, 0-16 days) for PTA/S-D (P  .001 for PTA/S-C
and PTA/S-D vs AK-FPB). Complications included one
death in the PTA/S-C group due to myocardial infarction
in a patient with tissue loss, and one puncture site pseudo-
aneurysm treated with thrombin injection. Postoperative
(30-day) SFA occlusion was seen only in one patient with
CLI in the PTA/S-D group. Rheolytic thrombectomy
(Angiojet, Possis Medical Inc, Minneapolis, Minn), throm-
bolysis, and placement of an additional stenting was initially
successful but reoccluded, necessitating a BK FPB with a
vein graft. One patient each in the PTA/S-C and PTA/S-D
groups had distal embolization, which was successfully
treated with rheolytic thrombectomy, followed by throm-
bolysis.
In the AK-FPB group, one patient had a nonfatal
myocardial infarction, one developed pneumonia and a
perigraft seroma necessitating operative débridement, one
developed an early graft infection necessitating graft re-
moval, and two patients had superficial wound infections
treated with débridement and local wound care. Although
other complication rates were similar among the groups,
occurrence of any infectious complication was significantly
more in the AK-FPB group than in the PTA/S groups
(8.7% vs 0%, P  .013).
Mean follow-up was 26.4 18.0 months (median, 24;
range, 0-70 months). The 12-, 24-, and 36-month primary
patency rates in the PTA/S-C group were 83%  6%, and
80%  7%, and 74%  8%, and in AK-FPB group were
81% 6%, 75% 7%, and 65% 8% (P .001 PTA/S-D
vs PTA/S-C and AK-FPB groups). The 12- and 24-month
primary patency rates in PTA/S-D group were 54%  8%
and 28% 12% (Fig 1). Primary patency for PTA/S-D was
significantly worse than both PTA/S-C (P  .001) and
AK-FPB (P  .001).
The 12-, 24-, and 36-month assisted-primary patency
rates in PTA/S-C group were 95%  3%, 95%  3%, and
95%  3% and in AK-FPB group were 81%  6%, 75% 
7%, and 65% 8%. The 12- and 24-month assisted-primary
patency rates in PTA/S-D group were 62% 8%, and 49%
10% (Fig 2). Assisted-primary patency was significantly
different among the three groups (P  .001, PTA/S-C vs
PTA/S-D; P  .003, PTA/S-C vs AK-FPB; and P  .03,
PTA/S-D vs AK-FPB).
The 12-, 24-, and 36-month secondary patency rates in
PTA/S-C group were 98% 3%, 98% 3%, and 98% 3%
and in the AK-FPB group were 81%  6%, 78%  7%, and
71% 8%. The 12- and 24-month secondary patency rates
in PTA/S-D group were 72% 7% and 54% 11% (Fig 3).
Secondary patency rates were significantly better in PTA/
S-C than AK-FPB (P  .003) and PTA/S-D groups (P 
.001); however, the difference was marginally better in the
AK-FPB than PTA/S-D group (P .064). In the AK-FPB
group, the patency rates were not affected by the TASC
class of the bypassed SFA (P  .31).The 24-month limb salvage rates were 95% 3%, 96%
3%, and 88%  6% in AK-FPB, PTA/S-C, and PTA/S-D
groups (P .190), and overall survival rates were 74% 7%,
mths primarily patent
363024181260
1.0
0.8
0.6
0.4
0.2
0.0
PTA/S-D-censored
PTA/S-C-censored
AK-FPB-censored
PTA/S-D
PTA/S-C
AK-FPB
Months 0 6 12 18 24 30 36 
AK-FPB 46 35 33 26 25 21 19 
PTA/S-C 49 41 34 24 21 9 8 
PTA/S-D 44 28 19 6 2 2 2 
Fig 1. Primary patency in percutaneous balloon angioplasty/
stenting in the TransAtlantic Inter-Society Consensus (TASC)-II
C group (PTA/S-C), in the TASC-II D group (PTA/S-D), and in
the above-knee (AK) femoropopliteal bypass (FPB) group (P 
.001). Hashed line indicates standard error 10%.
follow-up month assisted primary patency
363024181260
1.0
0.8
0.6
0.4
0.2
0.0
PTA/S-D-censored
PTA/S-C-censored
AK-FPB-censored
PTA/S-D
PTA/S-C
AK-FPB
Months 0 6 12 18 24 30 36 
AK-FPB 46 35 33 26 25 21 19 
PTA/S-C 49 49 38 28 26 15 14 
PTA/S-D 44 28 22 8 5 3 2 
Fig 2. Assisted-primary patency in percutaneous balloon angio-
plasty/stenting in the TransAtlantic Inter-Society Consensus
(TASC)-II C group (PTA/S-C), in the TASC-II D group (PTA/
S-D) and in the above-knee (AK) femoropopliteal bypass (FPB)
group (P  .001). Hashed line indicates standard error 10%.73% 7%, and 72% 8%, respectively (P .622).
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ment received, the 24-month primary patency for AK-FPB
(n 47), PTA/S-C (n 49), and PTA/S-D (n 37) was
76%  7%, 80%  7%, and 33%  14% (P  .01); 24-
month assisted-primary patency was 76% 7%, 95% 3%,
and 58%  12% (P  .002); and 24-month secondary
patency was 78%  7%, 98%  3%, and 64%  12% (P 
.005), respectively.
There was no statistically significant difference in coro-
nary artery disease (P  .958), renal insufficiency (P 
.227), hypertension (P  .408), hyperlipidemia (P 
.847), or smoking status (P .157), indication for surgery
(claudication vs CLI; P  .345), and three or fewer runoff
vessels (P  .678) on patency rates in any group. Interest-
ingly, we found at 24 months that patients with DM had a
better assisted-primary patency than non-DM patients
(82% 5% vs 65% 7%, P .05) and there was a trend for
patients with DM to have better primary patency (74% 
6% vs 55% 8%, P .056) and secondary patency (87%
4% vs 68%  7%, P  .062).
Despite the better patency rates, all limb loss occurred
in patients withDM, and the limb salvage rate at 36months
was significantly worse in patients with DM (86%  5% vs
100%, P  .009). We also found a trend for worse primary
patency at 24 months in the 52 IDDM patients compared
with the 29 NIDDMpatients (67% 8% vs 83% 7%, P
.162), whereas assisted-primary and secondary patency
rates were almost identical. We also noted that all limb loss
occurred in IDDM patients (24-month limb salvage,
follow-up months secondarily patent
363024181260
1.0
0.8
0.6
0.4
0.2
0.0
PTA/S-D-censored
PTA/S-C-censored
AK-FPB-censored
PTA/S-D
PTA/S-C
AK-FPB
Months 0 6 12 18 24 30 36 
AK-FPB 46 36 33 27 26 23 21 
PTA/S-C 49 49 39 29 27 16 15 
PTA/S-D 44 29 26 10 6 3 2 
Fig 3. Secondary patency in percutaneous balloon angioplasty/
stenting in the TransAtlantic Inter-Society Consensus (TASC)-II
C group (PTA/S-C), in the TASC-II D group (PTA/S-D) group,
and in the above-knee (AK) femoropopliteal bypass (FPB) group
(P  .001). Hashed line indicates standard error 10%.83%  6% vs 100%, P  .015).One patient had an early graft removal due to infection,
and 12 patients had graft occlusions 2 to 32 months after
FPB (median, 7; mean, 13 months). Three were asymp-
tomatic. Six had Angiojet thrombectomy, thrombolysis,
and inflow or runoff endovascular procedures. Four had
new bypass grafts, two of whom had a repeat occlusion of
their grafts after thrombolysis. One patient had recanaliza-
tion of his SFA without any attempt at salvaging the old
graft. Only one patient in this group had an amputation.
Only one patient had a PTA of his popliteal artery 68
months later, maintaining assisted-primary patency.
Seven patients in the PTA/S-C group underwent a
repeat intervention to maintain patency between 1 and 27
months after intervention. One was asymptomatic, and the
remaining had either nonhealing wounds (n 3) or recur-
rent claudication symptoms (n  3). Five of these had
cryoplasty of the in-stent restenosis, with or without addi-
tional debulking procedures. The remaining two had PTA
of runoff vessels. One patient required a repeat angioplasty
after recurrence of the in-stent restenosis. Five patients in
the PTA/S-D group had a repeat intervention for main-
taining assisted-primary patency 6 to 23 months after the
initial intervention. One was asymptomatic, and the re-
maining four had nonhealing wounds. One patient devel-
oped recurrent restenosis and underwent a second stenting
of his restenosed segment, and another who initially had a
nonhealing ulcer reoccluded 6 months later and remains a
claudicant.
Two symptomatic occlusions in PTA/S-C at 7 and 10
months were successfully treated by rheolytic thrombec-
tomy, thrombolysis, and additional stenting. There were
10 occlusions in the PTA/S-D patients between 0 and 23
months after the initial procedure (median, 6; mean, 6.3
months). Twowere asymptomatic, with healed wounds; six
patients underwent rheolytic thrombectomy plus throm-
bolysis, with additional endovascular intervention. Three of
these later reoccluded and underwent bypass procedures,
and one remained with mild claudication. One patient
underwent a bypass procedure after occlusion, and one had
a BKA.
In the PTA/S groups, six patients underwent bypass
procedures. One had an immediate bypass to AK popliteal
artery after crossing failed, and five had bypasses to the BK
popliteal segment at 0, 1, 2, 9, and 18 months after the
initial PTA/S procedure. After reviewing the angiograms,
we determined that four of these five patients would have
had a FPB to the BK popliteal artery and that the attempted
PTA/S did not affect the level of bypass. In the FPB group,
four patients had new bypass procedures 6, 7, 9, and 12
months after FPB, two of which were to the BK popliteal
artery using PTFE, and two were to infrapopliteal vessels (1
GSV, 1 PTFE).
No amputations were performed for any patient treated
for disabling claudication in this series. The 24-month limb
salvage rates for patients who presented with CLI were
95% 3%, 96% 3% and 88% 6% in FPB, PTA/S-C, and
PTA/S-D, respectively (P  .190). Ten amputations were
performed (3 in FPB, 2 in PTA/S-C, and 5 in PTA/S-D).
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the amputations occurred, despite a patent graft or stented
segment, due to extensive tissue loss after débridement for
infection control, or recurrent foot infection.
DISCUSSION
Although the number of endovascular interventions on
the SFA has dramatically increased to include more com-
plex lesions with long occlusions, surgical bypass remains
the recommended treatment for good-risk patients with
TASC C lesions, and TASC D lesions, in the TASC-II
document.21 However, these recommendations are mostly
based on historical data from results of bypass procedures
with different conduits, and very few reports on endovas-
cular treatment of long SFA occlusions (TASC C and D
lesions) are available on which to base these recommenda-
tions. Femoropopliteal bypass to the AK popliteal segment
using PTFE is a widely performed bypass procedure for
patients with SFA occlusions, and the treatment recom-
mendations in the TASC document do not specify the graft
type. However, after the initial sentinel report by Veith et
al26 suggesting comparable patency rates for AK-FPB with
vein and PTFE grafts, multiple studies have suggested that
there is a significant difference in patency rates between
PTFE and vein grafts in this location.28,29 A recent meta-
analysis of 75 studies suggested that a GSV graft to above
the knee had better patency29 and that this difference was
more pronounced in patients with CLI (24-month primary
patency, 65% vs 81%, 77% vs 84% in claudicant patients).
Our 24-month primary patency rate of 75% with PTFE
grafts is closer to the 77% primary patency in claudicant
patients in the meta-analysis, although nearly half of our
Table II. Reported patency rates of balloon angioplasty an
Author Pts/limbs CLI, % Le
Cheng3
(2003)
70/73 67 5 cm (m
Meuwissen7
(2004)
122/137 (87% B/C) NS 12.2 cm (5
Sabeti5
(2005)
65 20 10 cm (m
Suriewic1
(2005)
111 (C: 69, D: 42) 34 TAS
Schlager9
(2005)
170 12
45 SMa 139  8
125 DLb 125  8
Ferreira6
(2007)
59 (C: 16%, D: 61%) 15 19.2  1
Ko19
(2007)
106/121 NS 22.7  9
22.0  8
CLI, Critical limb ischemia; DM, diabetes mellitus; IL, intraluminal plus st
group; SP, secondary patency.
aSmart, Cordis, Johnson and Johnson, Miami Lakes, Fla.
bDynalink, Abbott Laboratories.Abbott Park, Ill.patients who had AK-FPB presented with CLI.The endovascular treatment of long SFA occlusions has
recently been reported to have increased patency rates,
especially with increased use of routine nitinol-based stent-
ing.6-9 Schillinger et al8 randomized 104 patients with
symptomatic SFA disease to primary stenting vs PTA plus
selective stenting, and the stented lengths of each group
were 127  55 and 132  71 mm. The 1-year restenosis
rates were 37% in primary stenting vs 63% in selective
stenting groups, respectively (P .01). The 1-year patency
rates of PTA/S of long segment SFA stenting with nitinol
stents has been 35% to 87% (Table II),1,3-9,19 with decreas-
ing patency in longer lesions and subgroups, such as DM
patients.5 Most of these studies included lesions in the
TASC-II C category, with the minority of lesions being in
the TASC D category. Our results with primary PTA/S of
long SFA occlusions in the TASC-II C category is favorable
compared with the reported literature, with a 2-year pri-
mary patency of 80% and secondary patency of 98%,
whereas the primary patency in TASC D was very poor
(28%). Our close surveillance protocol enabled us to im-
prove the patency rates in PTA/S groups, and most of the
occlusions were addressed by endovascular means, both of
which improved assisted-primary and secondary patency
rates in PTA/S groups.
Only a few studies have compared endovascular treat-
ment of long-segment SFA occlusions with bypasses. Ke-
dora et al22 randomized 100 limbs to AK-FPB using PTFE
graft vs covered stent (mean covered SFA length, 25.6 
15 cm), and reported an identical 12-month primary pa-
tency rate of 74% and secondary patency of 84% in both
groups. Surowiec et al1 reported their experience in 329
patients who underwent PTA/S of SFA lesions. They used
tinol stenting of long SFA occlusions
Tech success,
%
PP, % SP, 1
year,
%1 year 2 years
, 16 cm) NS 56 35 69
10 cm) 98 76 60
, 16 cm) NS 54 (DM, 22)
D 93 (incl all) C: 70; D: 50
(6 mo)
NS
87 66
78 64
m 90 78 96
(SI) 95 (SI) 72(SI)
(IL) 87 (IL) 51 (IL)
group; NS, not specified; PP, primary patency; SI, subintimal plus stentedd ni
ngth
edian
7% 
edian
C C/
8 mm
4 mm
0.8 c
.9 cm
.5 cm
entedself-expanding nitinol stents routinely in 69 patients with
JOURNAL OF VASCULAR SURGERY
November 20081172 Dosluoglu et alTASC C and 42 with TASC D lesions. They found that
FPB with synthetic graft performed similar to the TASC B
lesions; however, the 6-month patency of PTA/S of TASC
C and D lesions in their series was 70% and 50%, respec-
tively. The 12-month primary, assisted-primary and sec-
ondary patency rates of 80%  7%, 95%  3%, and 98% 
3% in our TASC-II C patients were significantly better than
patients who underwent AK-FPB using PTFE, although
our patency rates with TASC D lesions was significantly
worse than both groups.
Only TASCD lesions were found to be an independent
predictor of having poor primary, assisted-primary, and
secondary patency rates, when controlled for DM, number
of runoff vessels, coronary artery disease, hypertension,
renal insufficiency and hyperlipidemia. Previous reports
have also identified TASC D as being an independent
predictor of poorer patency31-33; however, most reports on
long SFA occlusions bundle TASC C and D lesions to-
gether, making it hard to detect any difference between the
two groups in terms of patency.2-6,34
When our results along with the literature are consid-
ered, we think that the results in TASC C and D patients
should be reported separately, because patients with TASC
D lesions clearly represent a different group with increased
atherosclerotic burden, and durability of endovascular in-
terventions are significantly worse in these patients. We also
think that the revised description of TASC-II C lesions,
with its inclusion of longer lesions in this category, is
appropriate; however, further studies are needed to evalu-
ate the difference between TASC-II B and C lesions, be-
cause the midterm patency rates in our patients with
TASC-II C lesions were very good. Incidentally, the pa-
tency did not seem to be affected by TASC category in
patients who underwent AK-FPB in our series.
The effect of DM on patency rates, and limb salvage
after endovascular interventions of the SFA has been incon-
sistent33-37 and is mostly influenced by the patient selection
criteria used in these retrospective analyses. DeRubertis et
al35 reported similar patency rates in claudicant patients,
whereas the patency was worse in those presenting with
CLI, although similar limb salvage could be achieved. In
contrast, Bakken et al33 reported similar patency rates in
those with CLI after endoluminal SFA interventions, yet
significantly worse limb salvage in patients with DM, with
12-month limb salvage of 89% in non-DM vs 67% in
NIDDM, and 73% in IDDM. They also found that patients
with IDDM who had claudication had worse patency,
whereas those with NIDDM had similar patency rates.
Interestingly, the DM patients in our study had better
assisted-primary patency rates at 24 months (82%  5% vs
65%  7%, P  .05), and although patients with IDDM
had somewhat worse primary patency at 24 months, this
did not reach statistical significance (67%  8% vs 83% 
7%, P  .162).
Despite the better patency rates, all limb loss occurred
in patients with DM (36-month limb salvage, 86%), and all
occurred in those with IDDM. It is important to note that
70% of our DM patients had tissue loss, and 74% of patientswith tissue loss had DM. Limb salvage rates in our study
were still acceptable in DM patients. Our patients fared
better than those in the Bakken et al series33 and were
similar to DeRubertis et al,35 who reported a 12-month
limb salvage of 88%.
The proponents of preferential treatment of all lesions
with endovascular means claim that this approach does not
have any negative effect on future interventions when re-
canalized vessels occlude.13,38 Gallaria et al38 reported that
early failure of SFA intervention was seen in 8% of their
patients who underwent SFA PTA/S (31% in TASCC, 41%
in TASC D); however, this did not have any negative effect
on the site of distal anastomosis or the level of amputation.
Joels et al39 found similar early failure rates (9%) after SFA
interventions and found that the distal target was changed
in about 30% of their patients. Endovascular reintervention
was feasible in most of these patients, and limb loss was
extremely rare. Our experience parallels these observations,
and the distal anastomosis site was changed from an AK to
a BK site only in one of six patients in whom a bypass was
eventually needed. In an additional patient, a second at-
tempt of PTA/S was successful 5 months later.
The main limitation of our study is that it is retrospec-
tive and nonrandomized in a predominantly male popula-
tion, and the number of patients in each group was rela-
tively small. In addition, most of the patients who had FPB
were treated before 2004, and patients in PTA/S group
were older, had more CLI, renal insufficiency, and fewer
runoff vessels, whereas there were more smokers in the FPB
group. These factors, however, did not have any effect on
patency rates and therefore did not seem to have any
significant effect on our overall findings.
CONCLUSIONS
PTA/S of TASC-II C lesions in SFA is found to be safe,
has excellent midterm patency rates, and performs better in
midterm than AK-FPB with PTFE graft, and PTA/S of
TASC D lesions. Thus, PTA/S should be the preferred
method of treatment in all TASC-II C lesions, if the alter-
native is AK-FPB with a PTFE graft. We also found that
PTA/S of TASC D lesions is safe, feasible in 84% of cases
when attempted, and it can achieve acceptable secondary
patency rates with excellent limb salvage. PTA/S in TASC
Dmay be considered as the first choice in high-risk patients,
especially in those with CLI. TASC-II C lesions should not
be grouped with TASC D, which represent patients with
more advanced disease and less durable results with endo-
vascular interventions. The type of bypass graft should be
included in the decision whether to choose endovascular or
open intervention for TASC-II C SFA lesions. We think
that a randomized study comparing PTA/S of TASC-II C
and D lesions to FPB using vein grafts should be consid-
ered, because the question of durability remains unan-
swered.
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